Wednesday, February 23, 2011
Friday, February 18, 2011
Tuesday, February 15, 2011
Quality of life of eye amputated patients - Rasmussen - 2011 - Acta Ophthalmologica - Wiley Online Library
Wednesday, February 09, 2011
Progressive Addition Lenses versus Single Vision Lenses for Slowing Progression of Myopia in Children with High Accommodative Lag and Near Esophoria — Invest. Ophthalmol. Vis. Sci.
Thursday, February 03, 2011
A Randomized Trial of Brimonidine Versus Timolol in Preserving Visual Function: Results From the Low-pressure Glaucoma Treatment Study
The effects of 2 week senofilcon—A silicone hydrogel contact lens daily wear on tear functions and ocular surface health status
Wednesday, February 02, 2011
Patient attitudes and behavior regarding hygiene and replacement of soft contact lenses and storage cases
Physical Activity, Television Viewing Time, and Retinal Vasc... : Medicine & Science in Sports & Exercise
A treatment for dry eye syndrome is to undergo a phase III randomized, placebo-controlled, multicentre study this year following a final licensing agreement with Celtic Therapeutics.
Resolvyx Pharmacuticals' RX-10045 is a resolvin that will be administered as a topical eye drop. In a large Phase II placebo-controlled study it was found that the eye drop produced dose-dependent, improvement on the primary endpoints for both signs and symptoms of dry eye, and was shown to be safe and well-tolerated.
Resolvins have demonstrated high potency and efficacy in the treatment of dry eye and retinal disease as well as asthma, rheumatoid arthritis, inflammatory bowel disease and atherosclerosis.
Stephen Evans-Freke and Peter B Corr, co-founders and Managing General Partners of Celtic Therapeutics Holdings, said: "We look forward to a close and successful alliance with Resolvyx to optimize the medical potential and financial returns from this exciting class of novel anti-inflammatory molecules in the ophthalmology field. If approved, RX-10045 should provide superior efficacy to current therapeutic options in dry eye. We are eager to explore the activity of resolvins in additional ophthalmic indications as well."